The other genes showing molecular alterations in prostate cancer samples from highest to lowest are as follows; FGF2 (94/4990; 1.9%), NFIB (86/4990; 1.7%), CEP43 (62/4990; 1.2%), GSK3B (99/8961; 1.1%), DICER1 (101/8961; 1.1%), NR3C1 (53/4990; 1.1%) and ABHD2 (28/4,990; 0.6%) (Supplementary Table S3). This evidence concerns the gene NFIB and prostate carcinoma.